Related Experiment Video

Updated: May 17, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin

John Wong1, Logan B Smith, Eli A Magun

  • 1School of Nursing, Oregon Health & Science University, Portland, OR, USA.

Cancer Biology & Therapy
|November 2, 2012
PubMed

Insights

This study shows ZAK kinase is crucial for doxorubicin-induced inflammation. Kinase inhibitors like nilotinib reduce these harmful inflammatory responses, potentially mitigating chemotherapy side effects.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Doxorubicin chemotherapy can cause severe side effects like cardiotoxicity and fatigue.
  • These adverse effects are linked to inflammatory cytokines regulated by mitogen-activated protein kinases (MAPKs).

Purpose of the Study:

  • To investigate the role of ZAK kinase in doxorubicin-induced MAPK activation and inflammatory responses.
  • To evaluate the efficacy of small molecule kinase inhibitors in suppressing these pathways.

Main Methods:

  • Utilized mouse primary macrophages from ZAK-deficient mice.
  • Assessed JNK and p38 MAPK phosphorylation and inflammatory gene/protein expression.
  • Administered kinase inhibitors (nilotinib, ponatinib, sorafenib) in vitro and in vivo.

Main Results:

  • ZAK deficiency prevented doxorubicin-mediated JNK and p38 MAPK activation.
  • Nilotinib, ponatinib, and sorafenib inhibited doxorubicin-induced MAPK phosphorylation.
  • These inhibitors reduced the expression and production of inflammatory mediators IL-1β, IL-6, and CXCL1.
  • Nilotinib co-administration decreased IL-1β and IL-6 levels in mice.

Conclusions:

  • ZAK is essential for doxorubicin's inflammatory signaling.
  • Targeting ZAK or downstream MAPKs with inhibitors may reduce doxorubicin-induced inflammation.
  • Identified kinase inhibitors show potential for minimizing chemotherapy-related side effects.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...